UY27499A1 - Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular - Google Patents

Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular

Info

Publication number
UY27499A1
UY27499A1 UY27499A UY27499A UY27499A1 UY 27499 A1 UY27499 A1 UY 27499A1 UY 27499 A UY27499 A UY 27499A UY 27499 A UY27499 A UY 27499A UY 27499 A1 UY27499 A1 UY 27499A1
Authority
UY
Uruguay
Prior art keywords
join
antibodies
human antibodies
neutralizing activity
cellular adhesion
Prior art date
Application number
UY27499A
Other languages
English (en)
Spanish (es)
Inventor
Toshihiko Takeuchi
Nathalie Dubois-Stringfellow
John E Murphy
Julie Rinkenberger
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of UY27499A1 publication Critical patent/UY27499A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UY27499A 2001-10-18 2002-10-17 Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular UY27499A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02

Publications (1)

Publication Number Publication Date
UY27499A1 true UY27499A1 (es) 2003-05-30

Family

ID=26993561

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27499A UY27499A1 (es) 2001-10-18 2002-10-17 Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular

Country Status (18)

Country Link
US (2) US7462696B2 (enExample)
EP (1) EP1438339A4 (enExample)
JP (2) JP2005528884A (enExample)
KR (1) KR20050037478A (enExample)
CN (1) CN1606569A (enExample)
AR (1) AR036833A1 (enExample)
BR (1) BR0213968A (enExample)
CA (1) CA2463943A1 (enExample)
CO (1) CO5370684A1 (enExample)
DO (1) DOP2002000494A (enExample)
HU (1) HUP0600335A2 (enExample)
IL (1) IL161411A0 (enExample)
MX (1) MXPA04003508A (enExample)
PE (1) PE20030473A1 (enExample)
PL (1) PL374304A1 (enExample)
RU (1) RU2317998C2 (enExample)
UY (1) UY27499A1 (enExample)
WO (1) WO2003033674A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7504365B2 (en) 2004-09-03 2009-03-17 Receptors Llc Combinatorial artificial receptors including tether building blocks
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
EP4001920A1 (en) * 2014-04-03 2022-05-25 AllerGenis, LLC Peptides and methods for detecting food allergy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
WO1995034650A2 (en) * 1994-06-15 1995-12-21 Ciba Corning Diagnostics Corp. Mn gene and protein
AU758957C (en) * 1998-10-23 2004-08-12 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Also Published As

Publication number Publication date
PE20030473A1 (es) 2003-06-26
CO5370684A1 (es) 2004-02-27
MXPA04003508A (es) 2004-07-22
RU2317998C2 (ru) 2008-02-27
WO2003033674A3 (en) 2003-08-21
CA2463943A1 (en) 2003-04-24
US20100240100A1 (en) 2010-09-23
DOP2002000494A (es) 2004-05-31
AR036833A1 (es) 2004-10-06
PL374304A1 (en) 2005-10-03
IL161411A0 (en) 2004-09-27
JP2010260845A (ja) 2010-11-18
KR20050037478A (ko) 2005-04-22
US7462696B2 (en) 2008-12-09
WO2003033674A2 (en) 2003-04-24
CN1606569A (zh) 2005-04-13
BR0213968A (pt) 2005-05-10
EP1438339A2 (en) 2004-07-21
HUP0600335A2 (en) 2006-08-28
US20030077277A1 (en) 2003-04-24
JP2005528884A (ja) 2005-09-29
EP1438339A4 (en) 2008-08-27
RU2004115112A (ru) 2005-04-27

Similar Documents

Publication Publication Date Title
AR036833A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
CY1121173T1 (el) Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
PE20050712A1 (es) Anticuerpos rg1
BRPI0314038B8 (pt) anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
BR9710811A (pt) Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
BR112021024544A2 (pt) Anticorpo monoclonal anti-ceacam5 e método de preparação do mesmo e uso do mesmo
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AR038568A1 (es) Anticuerpos anti-a beta y su uso
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
PE20071055A1 (es) Anticuerpos anti mn
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
AR040367A1 (es) Anticuerpos humanizados contra el receptor de linfotoxina beta
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
PE20221326A1 (es) Anticuerpos anti-mertk y metodos de uso de los mismos
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
ATE366746T1 (de) Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
CO2022006909A2 (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20151110